Condition

Platinum-Resistant Lung Small Cell Carcinoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common interventions9

Lead sponsors shown2

Clinical trials

3 shown

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerNCT05353439 · 2022-07-27

ACTIVE_NOT_RECRUITING

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerNCT04607954 · 2020-12-04

ACTIVE_NOT_RECRUITING

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the LungsNCT03896503 · 2019-12-30

ACTIVE_NOT_RECRUITING

Common interventions

Biopsy ProcedurePROCEDURE2 Biospecimen CollectionPROCEDURE2 Computed TomographyPROCEDURE2 Topotecan HydrochlorideDRUG2 BerzosertibDRUG1 DurvalumabBIOLOGICAL1 LurbinectedinDRUG1 PembrolizumabBIOLOGICAL1 Tazemetostat HydrobromideDRUG1

Leading sponsors

National Cancer Institute (NCI) 2 Mayo Clinic 1

Trial status mix

ACTIVE_NOT_RECRUITING3

Phase mix

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.